Baseline miR-210-5p showed strong diagnostic value for diabetes status in acute myocardial infarction patients (AUC 0.811; 95% CI 0.70-0.92; p=0.00006).
Observational (n=106)
Do specific microRNA signatures (miR-210, miR-21, miR-1-5p) correlate with diabetes status and predict disease severity in patients with acute myocardial infarction?
Specific microRNA signatures, particularly miR-210-5p and miR-1-5p, show potential as diagnostic and prognostic biomarkers for myocardial infarction severity and concurrent diabetes.
Effect estimate: AUC 0.811 (95% CI 0.70-0.92)
p-value: p=0.00006
Abstract Background Type 2 diabetes mellitus (T2DM) significantly increases the risk of myocardial infarction (MI), the leading cause of heart failure (HF) and a major contributor to mortality, with HF affecting approximately 17% of patients following severe acute MI (AMI). Aims We aimed to investigate miRNA expression changes by using bioinformatics tool and their associations with diabetes status, myocardial infarction severity, and predictive biomarkers. Methods In the EMPATHY trial, 106 patients with available baseline and 26-week plasma samples were included in the analysis of 212 longitudinal samples, with RNA analyses conducted. MiRNA expression quantified via qPCR, analyzed with statistical methods: ROC and multivariate logistic regression, to evaluate miRNA diagnostic value. Results miRNA expression changes in AMI patients based on diabetes status, with miR-210 increasing and miR-21 decreasing after 26 weeks in both groups, while miR-210 was lower and miR-195-5p higher in diabetes patients compared to non-diabetes patients at both time points (p0.05). In the acute phase of MI, diabetes patients had significantly higher miR-210-5p expression than non-diabetes patients (p0.0001), with baseline miR-210-5p showing strong diagnostic value (AUC = 0.811, 95% CI: 0.70–0.92, p = 0.00006) in ROC analysis. Patients with severe AMI had higher baseline miR-1-5p expression (p=0.002), which was associated with AMI severity (AUC: 0.748), and combining miR-1-5p with eGFR and NT-proBNP further improved predictive accuracy (AUC: 0.827, 95% CI: 0.70–0.96). Conclusion(s) MiR-210, miR-21, and miR-1-5p, showed a significant role in understanding the pathophysiology of AMI and its association with diabetes status and disease severity. The diagnostic value of miRNAs, suggests their potential as biomarkers for AMI, with combined panels such as miR-1-5p, eGFR, and NT-proBNP offering enhanced predictive accuracy.fig 1 fig 2
Ahmadova et al. (Sat,) conducted a observational in Acute myocardial infarction and Type 2 diabetes mellitus (n=106). Diabetes status vs. Non-diabetes status was evaluated on Diagnostic value of baseline miR-210-5p for diabetes status in acute phase of MI (AUC 0.811, 95% CI 0.70-0.92, p=0.00006). Baseline miR-210-5p showed strong diagnostic value for diabetes status in acute myocardial infarction patients (AUC 0.811; 95% CI 0.70-0.92; p=0.00006).